Latest & greatest articles for Systemic Lupus Erythematosus

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on Systemic Lupus Erythematosus or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on Systemic Lupus Erythematosus and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for Systemic Lupus Erythematosus

1. Belimumab (Benlysta ) - systemic lupus erythematosus

Belimumab (Benlysta ) - systemic lupus erythematosus belimumab | CADTH.ca Find the information you need belimumab belimumab Last Updated: October 1, 2019 Result type: Reports Project Number: SR0616-000 Product Line: Generic Name: Belimumab Brand Name: Benlysta Manufacturer: GlaxoSmithKline Inc. Indications: systemic lupus erythematosus Manufacturer Requested Reimbursement Criteria 1 : For the treatment of SLE patients who meet the following eligibility criteria: Adult patients age 18 years

2019 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

2. Trends in Maternal and Fetal Outcomes Among Pregnant Women With Systemic Lupus Erythematosus in the United States: A Cross-sectional Analysis. (PubMed)

Trends in Maternal and Fetal Outcomes Among Pregnant Women With Systemic Lupus Erythematosus in the United States: A Cross-sectional Analysis. Although pregnancy in systemic lupus erythematosus (SLE) carries a high risk for mother and fetus, outcomes may be improving.To assess nationwide trends and disparities in maternal and fetal complications among pregnant women with SLE.Retrospective cohort study.United States, 1998 to 2015.Adult pregnant women with and without SLE who had hospitalizations

2019 Annals of Internal Medicine

3. Novel paradigms in systemic lupus erythematosus. (PubMed)

Novel paradigms in systemic lupus erythematosus. The heterogeneity of systemic lupus erythematosus (SLE), long recognised by clinicians, is now challenging the entire lupus community, from geneticists to clinical investigators. Although the outlook for patients with SLE has greatly improved, many unmet needs remain, chief of which is the development of safer and more efficacious therapies. To develop innovative therapies, a far better understanding of SLE pathogenesis as it relates to the array (...) of clinical phenotypes is needed. Additionally, to efficiently achieve these goals, the lupus community needs to refine existing clinical research tools and better adapt them to overcome the obstacles created by the heterogeneity of manifestations. Here, we review progress towards the ultimate goal of safely reducing disease activity and preventing damage accrual and death. We discuss the new classification criteria from the European League Against Rheumatism and American College of Rheumatology, novel

2019 Lancet

4. Management strategies and future directions for systemic lupus erythematosus in adults. (PubMed)

Management strategies and future directions for systemic lupus erythematosus in adults. Systemic lupus erythematosus (SLE) is an autoimmune disease characterised by the loss of self-tolerance and formation of nuclear autoantigens and immune complexes resulting in inflammation of multiple organs. The clinical presentation of SLE is heterogeneous, can involve one or more organs, including the skin, kidneys, joints, and nervous system, and take a chronic or relapsing and remitting disease course

2019 Lancet

5. Comparison of Sensitivities of American College of Rheumatology and Systemic Lupus International Collaborating Clinics Classification Criteria in Childhood-onset Systemic Lupus Erythematosus

Comparison of Sensitivities of American College of Rheumatology and Systemic Lupus International Collaborating Clinics Classification Criteria in Childhood-onset Systemic Lupus Erythematosus Currently there are 2 different classification criteria for systemic lupus erythematosus (SLE): American College of Rheumatology (ACR) and Systemic Lupus International Collaborating Clinics (SLICC). The aim of this study was to compare the sensitivities of ACR and SLICC criteria in childhood-onset SLE (cSLE (...) ) using a large, multiethnic cohort.We conducted a retrospective study of 722 patients diagnosed with cSLE at The Hospital for Sick Children (SickKids). Prospectively collected data from SickKids' Lupus Database were reviewed/validated against medical records prior to ACR and SLICC scoring based on cumulative symptoms up to the last visit. Sensitivities were compared using McNemar's test. Descriptive statistics were used to identify SLE features unique to each set of criteria and autoantibodies

2019 EvidenceUpdates

6. Bidirectional relationship between systemic lupus erythematosus and non-Hodgkin`s lymphoma: a nationwide population-based study

Bidirectional relationship between systemic lupus erythematosus and non-Hodgkin`s lymphoma: a nationwide population-based study We conducted this nationwide population-based study in Taiwan to investigate whether there is a bidirectional relationship between SLE and non-Hodgkin's lymphoma (NHL).Using the National Health Insurance Research Database of Taiwan, we identified 16 417 patients with new-onset SLE without previous cancer and 25 069 patients with new-onset NHL without previous SLE

2019 EvidenceUpdates

7. Disease Damage Influences Cardiovascular Risk Reclassification Based on Carotid Ultrasound in Patients with Systemic Lupus Erythematosus

Disease Damage Influences Cardiovascular Risk Reclassification Based on Carotid Ultrasound in Patients with Systemic Lupus Erythematosus Composite scores of cardiovascular (CV) risk factors underestimate the CV risk in patients with systemic lupus erythematosus (SLE). Carotid artery ultrasound (US) was found useful in identifying high CV-risk patients with inflammatory arthritis. We assessed the effect of carotid US assessments on the CV risk stratification of patients with SLE.This cross (...) -sectional study included 276 patients with SLE. These indices were measured: lipid profile, Systematic COronary Risk Evaluation (SCORE) risk calculation, and disease activity (SLE Disease Activity Index), severity (Katz), and damage [Systemic Lupus International Collaborating Clinics (SLICC)/American College of Rheumatology Damage Index]. Carotid plaques were assessed by US. A multivariable regression analysis, adjusted for classic CV-related factors, was performed to evaluate how risk reclassification

2019 EvidenceUpdates

8. Relationship between disease activity, organ damage and health-related quality of life measurements assessed with SF-36, EQ-5D, LupusQol and LupusPRO in patients with systemic lupus erythematosus: a systemic review and meta-analysis

Relationship between disease activity, organ damage and health-related quality of life measurements assessed with SF-36, EQ-5D, LupusQol and LupusPRO in patients with systemic lupus erythematosus: a systemic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate

2019 PROSPERO

9. The expression of interferon-stimulated genes in peripheral blood mononuclear cells or the whole blood of patients with systemic lupus erythematosus compared to healthy controls: a systematic review

The expression of interferon-stimulated genes in peripheral blood mononuclear cells or the whole blood of patients with systemic lupus erythematosus compared to healthy controls: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears

2019 PROSPERO

10. A systematic review on medication therapies and their effectiveness on quality of life outcomes in patients with juvenile onset systemic lupus erythematosus

A systematic review on medication therapies and their effectiveness on quality of life outcomes in patients with juvenile onset systemic lupus erythematosus Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

11. Systemic lupus erythematosus (SLE)-related cognitive impairment and its effects on participation in social roles, quality of life and health status

Systemic lupus erythematosus (SLE)-related cognitive impairment and its effects on participation in social roles, quality of life and health status Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

12. Efficacy and safety of hydroxychloroquine/chloroquine in systemic lupus erythematosus: a systematic review and meta-analysis of randomized controlled trials and observational studies

Efficacy and safety of hydroxychloroquine/chloroquine in systemic lupus erythematosus: a systematic review and meta-analysis of randomized controlled trials and observational studies Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility

2019 PROSPERO

13. Serum adiponectin, leptin, resistin and insulin resistance levels in patients with systemic lupus erythematosus: a systematic review and meta-analysis

Serum adiponectin, leptin, resistin and insulin resistance levels in patients with systemic lupus erythematosus: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

14. Vitamin D status and systemic lupus erythematosus: a systematic review and meta-analysis

Vitamin D status and systemic lupus erythematosus: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites

2019 PROSPERO

15. Vitamin D status in paediatric onset of systemic lupus erythematosus: a systematic review and meta-analysis

Vitamin D status in paediatric onset of systemic lupus erythematosus: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

16. Symptom prevalence in patients with systemic lupus erythematosus (SLE) : a systematic review and meta-analysis

Symptom prevalence in patients with systemic lupus erythematosus (SLE) : a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

17. Efficacy of sifalimumab for treatment of skin injury (SI) caused by systemic lupus erythematosus (SLE): a systematic review protocol of randomized controlled trials

Efficacy of sifalimumab for treatment of skin injury (SI) caused by systemic lupus erythematosus (SLE): a systematic review protocol of randomized controlled trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability

2019 PROSPERO

18. Chinese herbal formulas on steroid withdrawal in systemic lupus erythematosus: a systematic review based on TCM therapeutic principle

Chinese herbal formulas on steroid withdrawal in systemic lupus erythematosus: a systematic review based on TCM therapeutic principle Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record

2019 PROSPERO

19. Canadian Rheumatology Association Recommendations for the Assessment and Monitoring of Systemic Lupus Erythematosus

Canadian Rheumatology Association Recommendations for the Assessment and Monitoring of Systemic Lupus Erythematosus To develop recommendations for the assessment of people with systemic lupus erythematosus (SLE) in Canada.Recommendations were developed using the GRADE (Grading of Recommendations Assessment, Development, and Evaluation) approach. The Canadian SLE Working Group (panel of Canadian rheumatologists and a patient representative from Canadian Arthritis Patient Alliance) was created

Full Text available with Trip Pro

2018 EvidenceUpdates

20. Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study. (PubMed)

Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study. Ustekinumab is a monoclonal antibody targeting interleukin (IL)-12 and IL-23 and is approved for the treatment of plaque psoriasis, psoriatic arthritis, and Crohn's disease. IL-12 and IL-23 have been implicated in systemic lupus erythematosus. We aimed to assess the efficacy and safety (...) of ustekinumab for the treatment of systemic lupus erythematosus in patients with moderate-to-severe disease activity despite conventional treatment.This was a multicentre, double-blind, phase 2, randomised, controlled trial of adult patients with active, seropositive systemic lupus erythematosus, done at 44 private practices and academic centres in Argentina, Australia, Germany, Hungary, Mexico, Poland, Spain, Taiwan, and the USA. Eligible adults were aged 18-75 years, weighed at least 35 kg, and had

2018 Lancet